Li et al. (2011) revealed an intrinsic HDAC inhibitor (HDACi)-resistant mechanism in cancer cells, suggesting that inhibiting the ATX-LPA axis could enhance the efficacy of HDACi-based therapies [24]. This evidence concerns the gene LPA and cancer.